| HOME >> MEDICINE >> TECHNOLOGY |
TABLE 77 CLINICAL PIPELINE AS OF 12/31/2009 130
TALECRIS BIOTHERAPEUTICS, INC. 131
TABLE 78 CLINICAL PIPELINE AS OF 12/31/2009 131
UCB SA 132
TABLE 79 CLINICAL PIPELINE AS OF 12/31/2009 132
URIGEN PHARMACEUTICALS, INC. 133
TABLE 80 CLINICAL PIPELINE AS OF 12/31/2009 133
VERTEX PHARMACEUTICALS INCORPORATED 133
TABLE 81 CLINICAL PIPELINE AS OF 12/31/2009 134
VICAL, INCORPORATED 134
TABLE 82 CLINICAL PIPELINE AS OF 12/31/2009 135
XOMA, LTD. 135
TABLE 83 CLINICAL PIPELINE AS OF 12/31/2009 136
Chapter-8: PHARMACEUTICAL COMPANIES
ABBOTT LABORATORIES 137
TABLE 84 CLINICAL PIPELINE HIGHLIGHTS AS OF 8/2010 137
ASTRAZENECA PLC 138
TABLE 85 CLINICAL PIPELINE AS OF 12/31/2009 138
TABLE 85 (CONTINUED) 139
TABLE 85 (CONTINUED) 140
TABLE 85 (CONTINUED) 141
BAYER SCHERING PHARMA AG 141
TABLE 86 PHASE II/III CLINICAL PIPELINE AS OF 12/31/2009 142
TABLE 86 (CONTINUED) 143
BOEHRINGER INGELHEIM GMBH 143
TABLE 87 CLINICAL PIPELINE AS OF 12/31/2009 144
BRISTOL-MYERS SQUIBB COMPANY 144
TABLE 88 CLINICAL PIPELINE, SELECTED PHASE I/II CANDIDATES AS OF 12/31/2009 145
TABLE 88 (CONTINUED) 146
TABLE 89 INVESTIGATIONAL CANDIDATES IN PHASE III CLINICAL TRIALS 146
ELI LILLY AND COMPANY 147
TABLE 90 CLINICAL PIPELINE HIGHLIGHTS AS OF 8/2010 147
GLAXOSMITHKLINE PLC 148
TABLE 91 CLINICAL PIPELINE AS OF 12/31/2009 148
TABLE 91 (CONTINUED) 149
TABLE 91 (CONTINUED) 150
TABLE 91 (CONTINUED) 151
TABLE 91 (CONTINUED) 152
JOHNSON & JOHNSON 152
TABLE 92 SELECTED PHASE III CLINICAL PIPELINE AS OF 12/31/2009 153
MERCK & CO., INC. 154
TABLE 93 CLINICAL PIPELINE AS OF 12/31/2009 154
TABLE 93 (CONTINUED) 155
M
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |